[1] Zhou X,Tan M,Stone Hawthorne V,et al. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers[J].Clin Cancer Res,2004,10(20):6779-6788.
[2] Staal SP,Hartley JW,Rowe WP. Isolation of transforming murine leukemia viruses from mice with a high incidence of spontaneous lymphoma[J]. Proc Natl Acad Sci U S A,1977,74(7):3065-3067.
[3] Tomare DA,Testa JR. Perturbations of the AKT signaling pathway in human cancer[J]. Oncogene,2005,24(50):7455.
[4] Stemke-Hale K,Gonzalez-Angulo AM,Lluch A,et al. An integrative genomic and proteomic analysis of PIK3CA,PTEN,and AKTmutations in breast cancer[J]. Cancer Res,2008,68(15):6084-6091.
[5] Manning BD,Cantley LC. AKT/PKB signaling: navigating downstream[J]. Cell,2007,129(7):1261-1274.
[6] Sheng S,Qiao M,Pardee AB. Metastasis and AKT activation[J].Cell Physiol,2009,218(3):451-454.
[7] Zhou H,Huang S. The complexes of mammalian target of rapamycin[J]. Curr Protein Pept Sci,2010,11(6):409-424.
[8] Sturgill TW,Hall MN. Activating mutations in TOR are in similar structures as oncogenic mutations in PI3KCalpha[J]. ACS Chem Biol,2009,4(12):999-1015.
[9] Potter CJ,Pedraza LG,Xu T. AKT regulates growth by directly phosphorylating TSC2[J]. Nat Cell Biol,2002,4(9):658-665.
[10] Gwinn DM,Shackelford DB,Egan DF,et al. AMPK phosphorylation of raptor mediates a metabolic checkpoint[J]. Mol Cell,2008,30(2):214-226.
[11] Guertin DA,Sabatini DM. Defining the role of mTOR in cancer[J]. Cancer Cell,2007,12(1):9-22.
[12] Peterson TR,Laplante M,Thoreen CC,et al. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myelomacells and required for their survival[J]. Cell,2009,137 (5):873-886.
[13] Adjei AA,Hidalgo M. Intracellular signal transduction pathway proteins as targets for cancer therapy[J]. Clin Oncol,2005,23(23):5386-5403.
[14] 陈英杰,刘健,陶雅君,等. PTEN、P13K 和 mTOR 在鼻咽癌中的表达及意义[J]. 现代肿瘤医学,2009,17(1):41-43.
[15] 陈鸥,李野,赵明金,等. PTEN 基因真核荧光表达载体的构建及其在喉癌细胞株中的表达[J]. 吉林大学学报:医学版,2009,5(35):817-820.
[16] Kinross KM,Montgomery KG,Kleinschmidt M,et al. An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice[J]. J Clin Invest,2012,122(2):553-557.
[17] Inoki K,Corradetti MN,Guan KL. Dysregulation of the TSC-mTOR pathway in human disease[J]. Nat Genet,2005,37(1):19-24.
[18] Ma L,Chen Z,Erdjumant-Bromage H,et al. Phosphorylation and funetiohal inactivation of TSC2 by Erk implications for tuberoug solerosis and cancer pathogenesis[J]. Cell,2005,121(2):179-193.
[19] Keller JA,Acosta-Jaquez HA,Foster KG,et al. Site-specific mTOR phosphorylation promotes mTORC1-mediated signaling and cell growth[J]. Mol Cell Biol,2009,29(15):4308-4324.
[20] Yang Q,Guan KL. Expanding mTOR signaling[J]. Cell Res,2007,17(8):666-681.
[21] Pontes HA,de Aquino Xavier FC,da Silva TS,et al.Metallothionein and p-Akt proteins in oral dysplasia and in oralsquamous cell carcinoma:an immunohistochemical study[J]. J Oral Pathol Med,2009,38(8):644-650.
[22] 刘发昱,李鹏,赵震锦,等. 人头颈鳞癌 CCR7 和 mTOR 表达关系研究[J]. 中国实用口腔科杂志,2011,4(7):407-409.
[23] Chakraborty S,Mohiyuddin SM,Gopinath KS,et al. Involvement of TSC genes and differential expression of other members of the mTOR signaling pathway in oral squamous cell carcinoma[J].BMC Cancer,2008,8:163.
[24] Silva BS,Yamamoto FP,Pontes FS,et al. TWIST and p-Akt immunoexpression in normal oral epithelium,oral dysplasia and in oral squamous cell carcinoma[J]. Med Oral Patol Oral Cir Bucal,2012,17(1):e29- e34.
[25] Pontes HA,de Aquino Xavier FC,da Silva TS. Metallothionein and p-Akt proteins in oral dysplasia and in oral squamous cell carcinoma:an immunohistochemical study[J]. Oral Pathol Med,2009,38(8):644-650.
[26] Naruse T,Kawasaki G,Yanamoto S,et al. Immunohistochemical study of VEGF expression in oral squamous cell carcinomas:correlation with the mTOR-HIF-1 pathway[J]. Anticancer Res,2011,31(12):4429-4437.
[27] 刘奕,杨鸣良,张扬,等. 哺乳动物的雷帕霉素靶蛋白及其底物在口腔鳞状细胞癌中的表达[J]. 华西口腔医学杂志,2004,22(4):331-333.
[28] Uesugi A,Kozaki K,Tsuruta T,et al. The tumor suppressive microRNA miR-218 targets the mTOR component Rictor andinhibits AKT phosphorylation in oral cancer[J]. Cancer Res,2011,71(17):5765-5778.
[29] Kapoor V,Zaharieva MM,Das SN,et al. Erufosine simultaneously induces apoptosis and autophagy by modulating the Akt-mTOR signaling pathway in oral squamous cell carcinoma[J]. Cancer Lett,2012,19(1):39-48.